Search News Archives
Special Offers and Promotions
Conferences | Events
Gyros Protein Technologies Introduces Gyrolab xPand to Improve Immunoassay Workflow, Flexibility and Speed in Biotherapeutic Discovery, Development and Production
Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassay platforms and leading provider of peptide synthesizers and reagents, has introduced a new 5 CD model, Gyrolab® xPand, in response to customer requests to provide higher throughput, greater flexibility and faster analysis of large sample numbers.
Gyrolab technology significantly accelerates the process of discovering and developing new and safer biotherapeutics. The introduction of Gyrolab xPand reflects the on-going evolution of the Gyrolab platform, with ever more advanced instrumentation and software designed for 21 CFR part 11 compliance. During assay runs, the new multi-CD platform maintains samples at 2 – 8°C, diminishing the possible adverse effects of on-board sample storage. As an open platform with built-in flexibility, Gyrolab xPand can be adapted to the specific needs of each user for example, different assays can be mixed within a 5 CD run, while maintaining high quality results. Scientists will continue to increase their productivity with the new Gyrolab software capabilities for desktop experiment planning, experiment mapping, as well as advanced functions for dilution linearity and spike recovery studies for assay qualification.
Gyrolab technology includes optimized, ready-to-use kits for cell line development, bioprocessing applications and pre-clinical PK/TK, simplifying assay workflow and shortening run times. Some clients have reported a 40% reduction in project times versus alternative technologies. The proprietary Gyrolab CD technology, with highly reproducible nanoliter microfluidics, is integrated with Gyrolab platforms to automate nanoliter-scale immunoassays with parallel processing, using laser-induced fluorescence detection.
Dan Calvo, CEO & President Gyros Protein Technologies, said: “The majority of the world’s leading biopharmaceutical companies and CROs use Gyrolab technology in discovery, preclinical and clinical development, and bioprocess. They regard the system as a ‘must-have’ to accelerate assay development, sample analysis, and production. Therefore, it is essential that our instrument portfolio expands to address additional requirements from our customers. Gyrolab xPand combines the best features of the Gyrolab platform with the addition of cooling, and many new software capabilities to increase productivity and performance that our customers demand.”